HC Wainwright Has Lowered Expectations for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) had its price objective lowered by equities research analysts at HC Wainwright from $80.00 to $32.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 112.60% from the company's current price.

Other research analysts also recently issued research reports about the company. Robert W. Baird assumed coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target on the stock. Baird R W raised shares of Denali Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 7th. The Goldman Sachs Group lowered their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Bank of America cut their price objective on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Denali Therapeutics presently has a consensus rating of "Buy" and an average target price of $33.79.

Denali Therapeutics Trading Up 4.7%

NASDAQ:DNLI traded up $0.68 during midday trading on Wednesday, reaching $15.05. The company had a trading volume of 675,968 shares, compared to its average volume of 1,090,906. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $33.33. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -5.46 and a beta of 1.49. The stock's fifty day simple moving average is $14.27 and its 200-day simple moving average is $19.99.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period last year, the business posted ($0.68) earnings per share. As a group, sell-side analysts expect that Denali Therapeutics will post -2.71 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DNLI. Sterling Capital Management LLC raised its stake in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after acquiring an additional 1,516 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Denali Therapeutics during the fourth quarter worth about $62,000. Point72 Hong Kong Ltd acquired a new position in Denali Therapeutics during the fourth quarter valued at approximately $65,000. PNC Financial Services Group Inc. increased its stake in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after purchasing an additional 885 shares during the period. Finally, GAMMA Investing LLC increased its stake in Denali Therapeutics by 253.8% during the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock worth $108,000 after acquiring an additional 5,705 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.